Melden
Teilen
![[object Object],Mission Statement](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Empfohlen
Oncology initiatives in Women’s Healthcare have gained another valuable therapy to improve patient care and outcomes…
Merck & Co.’s ( NYSE: MRK )Keytruda and combination partner therapy Eisai’s ( OTCMKTS: ESALY ) Lenvima will keep their respective marketing and sales units very busy in the upcoming months. Regulatory agencies in the United States, Canada and Australia have concurrently approval to the Keytruda-Lenvima tandem for women with certain advanced endometrial carcinoma. It represents a significant accomplishment by Merck and Eisai and for government regulatory agencies working together to accelerate the process of advancing medicine whether it’s for completely new products or clinically strategic new indications.
Project Orbis: Improve accuracy and accelerate new drug and indication approvals across multiple nation government agencies...
The parallel decisions are the first made through Project Orbis ;a collaborative initiative of the Food And Drug Administration ( FDA ), the Australian Therapeutic Goods Administration ( TGA ) and Health Canada that seeks to reduce new oncology therapy review turnaround between nations. It champions concurrent submissions by drug manufacturers and collaborative assessments by each of the three government regulatory agencies, sponsors and collaborative reviews by all three agencies.
Project Orbis: A winning initiative for patients and clinicians
New drug approvals and the process of approving additional indications is a detail heavy exercise necessary to qualify performance and safety of medications. By improving the processes within nations and cultivating collaboration between them, patients and clinicians benefit from having access to approved therapies sooner. For advanced medication, payers are often reluctant to cover their costs without specific regulatory approval of precise indications. Project Orbis initiatives helps to overcome this hurdle.
Read the article for complete details and contact John Baresky for further information...Merck Keytruda and Eisai Lenvima Achieve Triple Approval In Oncology And Wome...
Merck Keytruda and Eisai Lenvima Achieve Triple Approval In Oncology And Wome...Bare Sky Marketing Healthcare Content Writing Services
Empfohlen
Oncology initiatives in Women’s Healthcare have gained another valuable therapy to improve patient care and outcomes…
Merck & Co.’s ( NYSE: MRK )Keytruda and combination partner therapy Eisai’s ( OTCMKTS: ESALY ) Lenvima will keep their respective marketing and sales units very busy in the upcoming months. Regulatory agencies in the United States, Canada and Australia have concurrently approval to the Keytruda-Lenvima tandem for women with certain advanced endometrial carcinoma. It represents a significant accomplishment by Merck and Eisai and for government regulatory agencies working together to accelerate the process of advancing medicine whether it’s for completely new products or clinically strategic new indications.
Project Orbis: Improve accuracy and accelerate new drug and indication approvals across multiple nation government agencies...
The parallel decisions are the first made through Project Orbis ;a collaborative initiative of the Food And Drug Administration ( FDA ), the Australian Therapeutic Goods Administration ( TGA ) and Health Canada that seeks to reduce new oncology therapy review turnaround between nations. It champions concurrent submissions by drug manufacturers and collaborative assessments by each of the three government regulatory agencies, sponsors and collaborative reviews by all three agencies.
Project Orbis: A winning initiative for patients and clinicians
New drug approvals and the process of approving additional indications is a detail heavy exercise necessary to qualify performance and safety of medications. By improving the processes within nations and cultivating collaboration between them, patients and clinicians benefit from having access to approved therapies sooner. For advanced medication, payers are often reluctant to cover their costs without specific regulatory approval of precise indications. Project Orbis initiatives helps to overcome this hurdle.
Read the article for complete details and contact John Baresky for further information...Merck Keytruda and Eisai Lenvima Achieve Triple Approval In Oncology And Wome...
Merck Keytruda and Eisai Lenvima Achieve Triple Approval In Oncology And Wome...Bare Sky Marketing Healthcare Content Writing Services
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (19)
Supply chain and delivery of antimicrobial drugs in smallholder livestock pro...
Supply chain and delivery of antimicrobial drugs in smallholder livestock pro...
mHealth Israel_Rambam Health Care Campus_Miki Halberthal
mHealth Israel_Rambam Health Care Campus_Miki Halberthal
mHealth Israel_E-Health to Digital Health_Jeremy Brody_Kantar Health
mHealth Israel_E-Health to Digital Health_Jeremy Brody_Kantar Health
Complete Prior Authorization Services | Prior Authorization Process Guideline
Complete Prior Authorization Services | Prior Authorization Process Guideline
UCPMP guidelines pharma marketing code by http://www.dailyrounds.org/blog/ucp...
UCPMP guidelines pharma marketing code by http://www.dailyrounds.org/blog/ucp...
Current mci guidelines for pharmaceutical companies and government
Current mci guidelines for pharmaceutical companies and government
Dr Alessandro Roncacci, Health Innovation Conference 2021
Dr Alessandro Roncacci, Health Innovation Conference 2021
All You Need To Know About Insurance Prior Authorizations In Healthcare
All You Need To Know About Insurance Prior Authorizations In Healthcare
mHealth Israel_Payers, Providers & Reimbursement_Amir Inbar_Mediclever
mHealth Israel_Payers, Providers & Reimbursement_Amir Inbar_Mediclever
Ähnlich wie SafetyCall International
Ähnlich wie SafetyCall International (20)
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Virtual Workshop Innovative Approaches to Drug Safety 2019
Virtual Workshop Innovative Approaches to Drug Safety 2019
TITAN Group & TVMA Webinar: Safeguarding Your Controlled Substances
TITAN Group & TVMA Webinar: Safeguarding Your Controlled Substances
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
Healthcare Sector Analysis PowerPoint Presentation Slides
Healthcare Sector Analysis PowerPoint Presentation Slides
SafetyCall International
- 13. SafetyCall International, PLLC Please contact us! [email_address] 866-327-7282 www.safetycall.com